罕见神经疾病制药公司Harmony Biosciences Holdings, Inc.（股票代码：HRMY）今日盘中股价大涨5.17%，引起市场广泛关注。
根据公司发布的财报显示，Harmony Biosciences第一季度表现优异，多项财务指标均超出市场预期。公司第一季度每股收益达到78美分，远高于分析师预期的58美分。同时，第一季度产品收入为1.8473亿美元，也超过了分析师预计的1.829亿美元。这些亮眼的业绩数据无疑提振了投资者信心。
值得注意的是，尽管近期股价表现不佳，Harmony Biosciences仍然维持了其2025年8.2亿至8.6亿美元的产品营收预期，高于市场预期的8.3989亿美元。这一举措表明公司对未来业务增长保持乐观态度，进一步巩固了投资者对公司长期发展前景的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.